.. Première-autogreffe:-modalité-et-réponse, 70 a) Traitement d'induction, p.70

.. Seconde-autogreffe:-modalité-et-réponse, 74 a) Traitement d'induction 74 b), p.75

.. Analyse-univariée, Variables ayant un impact significatif sur la survie 83 a) La qualité de la réponse après la première intensification-autogreffe 83 b) Le nombre de ligne de traitement avant intensification-autogreffe en rechute 86 d) Le temps jusqu'à progression après la première intensification-autogreffe, 84 c) L'exposition ou non aux nouvelles molécules e) La qualité de la réponse après autogreffe en rechute, p.91

V. Bibliographie-1, M. Cavo, S. Rajkumar, A. Palumbo, P. Moreau et al., International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation, Blood, vol.117, issue.23, pp.6063-73, 20119.

J. Bladé, L. Rosiñol, M. Cibeira, M. Rovira, and E. Carreras, Hematopoietic stem cell transplantation for multiple myeloma beyond 2010, Blood, vol.115, issue.18, pp.3655-63, 2010.
DOI : 10.1182/blood-2009-08-238196

S. Kumar, S. Rajkumar, A. Dispenzieri, M. Lacy, S. Hayman et al., Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, issue.5, pp.2516-2536, 2008.
DOI : 10.1182/blood-2007-10-116129

S. Solly, Remarks on the Pathology of Mollities Ossium. With Cases, Journal of the Royal Society of Medicine, vol.27, issue.1, pp.435-498, 1844.
DOI : 10.1177/095952874402700129

R. Kyle and S. Rajkumar, Multiple myeloma. Blood, mars, vol.15111, issue.6, pp.2962-72, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00557757

O. Landgren, R. Kyle, R. Pfeiffer, J. Katzmann, N. Caporaso et al., Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study, Blood, vol.113, issue.22, pp.5412-5419, 2009.
DOI : 10.1182/blood-2008-12-194241

R. Kyle, T. Therneau, S. Rajkumar, J. Offord, D. Larson et al., A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.346, issue.8, pp.564-573, 2002.
DOI : 10.1056/NEJMoa01133202

J. Harousseau and P. Moreau, Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.360, issue.25, pp.2645-54, 2009.
DOI : 10.1056/NEJMct0805626

R. Kyle and S. Rajkumar, Treatment of Multiple Myeloma: A Comprehensive Review, Clinical Lymphoma and Myeloma, vol.9, issue.4, pp.278-88, 2009.
DOI : 10.3816/CLM.2009.n.056

C. Hulin, T. Facon, P. Rodon, B. Pegourie, L. Benboubker et al., Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial, Journal of Clinical Oncology, vol.27, issue.22, pp.3664-70, 2009.
DOI : 10.1200/JCO.2008.21.0948

L. Terriou, X. Leleu, and I. Yakoub-agha, Treatment of multiple myeloma]. Bull Cancer Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br. J. Haematol, vol.93121, issue.15, pp.101-107, 2003.

R. Kyle and S. Rajkumar, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, vol.22, issue.1, pp.3-9, 2009.
DOI : 10.1038/leu.2008.291

B. Durie and S. Salmon, A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.126, issue.3, pp.842-54, 1975.
DOI : 10.3181/00379727-125-32327

R. Bataille, B. Durie, and J. Grenier, microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging., British Journal of Haematology, vol.26, issue.3, pp.439-486, 1983.
DOI : 10.1080/22953337.1980.11718773

P. Greipp, S. Miguel, J. Durie, B. Crowley, J. Barlogie et al., International Staging System for Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.15, pp.3412-3432, 2005.
DOI : 10.1200/JCO.2005.04.242

H. Avet-loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban et al., Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, vol.109, issue.8, pp.3489-95, 2007.
DOI : 10.1182/blood-2006-08-040410

J. Drach, J. Schuster, H. Nowotny, J. Angerler, F. Rosenthal et al., Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization, Cancer Res, vol.55, issue.17, pp.3854-3863, 1995.

R. Fonseca, P. Bergsagel, J. Drach, J. Shaughnessy, N. Gutierrez et al., International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, Leukemia, vol.91, issue.12, pp.2210-2231, 2009.
DOI : 10.1016/j.beha.2007.08.004

A. Stewart, P. Bergsagel, P. Greipp, A. Dispenzieri, M. Gertz et al., A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy, Leukemia, vol.105, issue.3, pp.529-563, 2007.
DOI : 10.7326/0003-4819-115-12-931

R. Fonseca, V. Wier, S. Chng, W. Ketterling, R. Lacy et al., Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma, Leukemia, vol.91, issue.Suppl 1, pp.2034-2074, 2006.
DOI : 10.1016/j.ccr.2006.03.019

N. Munshi, K. Anderson, P. Bergsagel, J. Shaughnessy, A. Palumbo et al., Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2, Blood, vol.117, issue.18, pp.4696-700, 2011.
DOI : 10.1182/blood-2010-10-300970

B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari et al., Treatment of multiple myeloma. Blood, pp.20-32, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00368414

A. Vacca, D. Ribatti, L. Roncali, G. Ranieri, G. Serio et al., Bone marrow angiogenesis and progression in multiple myeloma, British Journal of Haematology, vol.324, issue.3, pp.503-511, 1994.
DOI : 10.1002/1097-0142(19930715)72:2<455::AID-CNCR2820720222>3.0.CO;2-8

X. Armoiry, Prise en charge du mélome multiple : traitement standard et nouveautés thérapeutiques, J Pharm Clin, vol.26, issue.1, pp.33-42, 2007.

P. Richardson and K. Anderson, Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma, Journal of Clinical Oncology, vol.22, issue.16, pp.3212-3216, 2004.
DOI : 10.1200/JCO.2004.05.984

S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson et al., Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, New England Journal of Medicine, vol.341, issue.21, pp.1565-71, 1999.
DOI : 10.1056/NEJM199911183412102

P. Richardson, R. Schlossman, E. Weller, T. Hideshima, C. Mitsiades et al., Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma, Blood, vol.100, issue.9, pp.3063-3070, 2002.
DOI : 10.1182/blood-2002-03-0996

A. Palumbo, S. Rajkumar, M. Dimopoulos, P. Richardson, S. Miguel et al., Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma, Leukemia, vol.305, issue.2, pp.414-437, 2008.
DOI : 10.1056/NEJMoa025313

M. Dimopoulos, A. Alegre, E. Stadtmauer, H. Goldschmidt, J. Zonder et al., The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function, Cancer, vol.10, issue.16, pp.3807-3821, 2010.
DOI : 10.1002/cncr.25139

C. Aghajanian, S. Soignet, D. Dizon, C. Pien, J. Adams et al., A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies, Clin. Cancer Res, vol.8, issue.8, pp.2505-2516, 2002.

P. Richardson, H. Briemberg, S. Jagannath, P. Wen, B. Barlogie et al., Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib, Journal of Clinical Oncology, vol.24, issue.19, pp.3113-3133, 2006.
DOI : 10.1200/JCO.2005.04.7779

B. Mohty, J. El-cheikh, I. Yakoub-agha, P. Moreau, J. Harousseau et al., Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations, Haematologica, vol.95, issue.2, pp.311-320, 2010.
DOI : 10.3324/haematol.2009.012674

A. Chanan-khan, J. Kaufman, J. Mehta, P. Richardson, K. Miller et al., Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study, Blood, vol.109, issue.6, pp.2604-2610, 2007.
DOI : 10.1182/blood-2006-09-046409

M. Attal, J. Harousseau, A. Stoppa, J. Sotto, J. Fuzibet et al., A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, New England Journal of Medicine, vol.335, issue.2, pp.91-98, 1996.
DOI : 10.1056/NEJM199607113350204

J. Child, G. Morgan, F. Davies, R. Owen, S. Bell et al., High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma, New England Journal of Medicine, vol.348, issue.19, pp.1875-83, 2003.
DOI : 10.1056/NEJMoa022340

J. Koreth, C. Cutler, B. Djulbegovic, R. Behl, R. Schlossman et al., High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials, Biology of Blood and Marrow Transplantation, vol.13, issue.2, pp.183-96, 2007.
DOI : 10.1016/j.bbmt.2006.09.010

P. Moreau, H. Avet-loiseau, J. Harousseau, and M. Attal, Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies, Journal of Clinical Oncology, vol.29, issue.14, pp.1898-906, 2011.
DOI : 10.1200/JCO.2010.32.5878

M. Attal, J. Harousseau, T. Facon, F. Guilhot, C. Doyen et al., Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.349, issue.26, pp.2495-502, 2003.
DOI : 10.1056/NEJMoa032290

M. Cavo, P. Tosi, E. Zamagni, C. Cellini, P. Tacchetti et al., Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study, Journal of Clinical Oncology, vol.25, issue.17, pp.2434-2475, 2007.
DOI : 10.1200/JCO.2006.10.2509

M. Roussel, P. Moreau, A. Huynh, J. Mary, C. Danho et al., Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM), Blood, vol.115, issue.1, pp.32-39, 2010.
DOI : 10.1182/blood-2009-06-229658

J. Harousseau, Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma, Haematologica, vol.84, issue.6, pp.548-53, 1999.

C. Weaver, B. Hazelton, R. Birch, P. Palmer, C. Allen et al., An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy, Blood. nov, vol.1586, issue.10, pp.3961-3970, 1995.

W. Bensinger, F. Appelbaum, S. Rowley, R. Storb, J. Sanders et al., Factors that influence collection and engraftment of autologous peripheral-blood stem cells., Journal of Clinical Oncology, vol.13, issue.10, pp.2547-55, 1995.
DOI : 10.1200/JCO.1995.13.10.2547

S. Giralt, E. Stadtmauer, J. Harousseau, A. Palumbo, W. Bensinger et al., International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100), Leukemia, vol.21, issue.10, pp.1904-1916, 2009.
DOI : 10.1038/sj.leu.2404284

N. Flomenberg, S. Devine, J. Dipersio, J. Liesveld, J. Mccarty et al., The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone, Blood, vol.106, issue.5, pp.1867-74, 2005.
DOI : 10.1182/blood-2005-02-0468

J. Harousseau, Ten years of improvement in the management of multiple myeloma

M. Cavo, E. Zamagni, P. Tosi, P. Tacchetti, C. Cellini et al., Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma, Blood, vol.106, issue.1, pp.35-44, 2005.
DOI : 10.1182/blood-2005-02-0522

J. Harousseau, M. Attal, H. Avet-loiseau, G. Marit, D. Caillot et al., Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial, Journal of Clinical Oncology, vol.28, issue.30, pp.4621-4630, 2010.
DOI : 10.1200/JCO.2009.27.9158

S. Kumar, A. Dispenzieri, M. Lacy, S. Hayman, F. Buadi et al., Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma, Leukemia, vol.16, issue.9, pp.2035-2077, 2007.
DOI : 10.1007/s002770100351

T. Mark, J. Stern, J. Furst, D. Jayabalan, F. Zafar et al., Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma, Biology of Blood and Marrow Transplantation, vol.14, issue.7, pp.795-803, 2008.
DOI : 10.1016/j.bbmt.2008.04.008

M. Cavo, P. Tacchetti, F. Patriarca, M. Petrucci, L. Pantani et al., Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study, The Lancet, vol.376, issue.9758, pp.2075-85, 2010.
DOI : 10.1016/S0140-6736(10)61424-9

P. Moreau, H. Avet-loiseau, T. Facon, M. Attal, M. Tiab et al., Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma, Blood, vol.118, issue.22, pp.5752-5758, 2011.
DOI : 10.1182/blood-2011-05-355081

M. Roussel, H. Avet-loiseau, P. Moreau, A. Huynh, L. Benboubker et al., Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 20, -Frontline Therapy with Bortezomib-Miguel JF. How I treat multiple myeloma in younger patients, p.624, 2010.

S. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. Greipp, Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group, Journal of Clinical Oncology, vol.24, issue.3, pp.431-437, 2006.
DOI : 10.1200/JCO.2005.03.0221

R. Popat, H. Oakervee, S. Hallam, N. Curry, L. Odeh et al., Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up, British Journal of Haematology, vol.9, issue.2, pp.512-518, 2008.
DOI : 10.1056/NEJMoa043445

M. Cavo, N. Testoni, C. Terragna, G. Marzocchi, S. Durante et al., Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide- Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial, ASH Annual Meeting Abstracts. Leukemia, vol.11223, issue.117, pp.1337-1378, 2008.

P. Richardson, E. Weller, S. Lonial, A. Jakubowiak, S. Jagannath et al., Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma, Blood, vol.116, issue.5, pp.679-86, 2010.
DOI : 10.1182/blood-2010-02-268862

J. Harousseau, H. Avet-loiseau, M. Attal, C. Charbonnel, F. Garban et al., Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials, Journal of Clinical Oncology, vol.27, issue.34
DOI : 10.1200/JCO.2008.21.1060

URL : https://hal.archives-ouvertes.fr/hal-00821143

J. Martinez-lopez, J. Blade, M. Mateos, C. Grande, A. Alegre et al., Long-term prognostic significance of response in multiple myeloma after stem cell transplantation, Blood, vol.118, issue.3, pp.529-563, 2011.
DOI : 10.1182/blood-2011-01-332320

A. Chanan-khan and S. Giralt, Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents, Journal of Clinical Oncology, vol.28, issue.15, pp.2612-2636, 2010.
DOI : 10.1200/JCO.2009.25.4250

S. Rajkumar, J. Harousseau, B. Durie, K. Anderson, M. Dimopoulos et al., Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, vol.117, issue.18, pp.4691-4696, 2011.
DOI : 10.1182/blood-2010-10-299487

M. Ladetto, G. Pagliano, S. Ferrero, F. Cavallo, D. Drandi et al., Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma, Journal of Clinical Oncology, vol.28, issue.12, pp.2077-84, 2010.
DOI : 10.1200/JCO.2009.23.7172

U. Mellqvist, J. Westin, O. Hjertner, S. Lenhoff, E. Laane et al., Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial in BLOOD, pp.221-221, 2009.

B. Brinker, E. Waller, T. Leong, L. Heffner, . Jr et al., Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer, pp.2171-80, 2006.

A. Stewart, C. Chen, K. Howson-jan, D. White, J. Roy et al., Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant, Clinical Cancer Research, vol.10, issue.24, pp.8170-8176, 2004.
DOI : 10.1158/1078-0432.CCR-04-1106

D. Reece, Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma, Hematology, vol.2011, issue.1, pp.197-204, 2011.
DOI : 10.1182/asheducation-2011.1.197

M. Attal, J. Harousseau, S. Leyvraz, C. Doyen, C. Hulin et al., Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, Blood, vol.108, issue.10, pp.3289-94, 2006.
DOI : 10.1182/blood-2006-05-022962

B. Barlogie, M. Pineda-roman, F. Van-rhee, J. Haessler, E. Anaissie et al., Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities, Blood, vol.112, issue.8, pp.3115-3136, 2008.
DOI : 10.1182/blood-2008-03-145235

A. Spencer, H. Prince, A. Roberts, I. Prosser, K. Bradstock et al., Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure, Journal of Clinical Oncology, vol.27, issue.11, pp.1788-93, 2009.
DOI : 10.1200/JCO.2008.18.8573

B. Barlogie, M. Attal, J. Crowley, F. Van-rhee, J. Szymonifka et al., Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences, Journal of Clinical Oncology, vol.28, issue.7, pp.1209-1223, 2010.
DOI : 10.1200/JCO.2009.25.6081

M. Attal, V. Lauwers-cances, G. Marit, D. Caillot, P. Moreau et al., Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.366, issue.19, pp.1782-91, 2012.
DOI : 10.1056/NEJMoa1114138

URL : https://hal.archives-ouvertes.fr/hal-00852275

P. Sonneveld, H. Ludwig, B. Durie, P. Mccarthy, A. Palumbo et al., Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM), IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 mars 29, pp.40-653003, 2009.

B. Barlogie, E. Anaissie, F. Van-rhee, J. Haessler, K. Hollmig et al., Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3, British Journal of Haematology, vol.109, issue.2
DOI : 10.1056/NEJMoa022340

. J. Br, F. Van-rhee, J. Szymonifka, E. Anaissie, B. Nair et al., Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood, pp.176-851220, 2007.

H. Brenner, A. Gondos, and D. Pulte, Recent major improvement in long-term survival of younger patients with multiple myeloma, Blood, vol.111, issue.5, pp.2521-2527, 2008.
DOI : 10.1182/blood-2007-08-104984

J. Harousseau, M. Dimopoulos, M. Wang, A. Corso, C. Chen et al., Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma, Haematologica, vol.95, issue.10, pp.1738-1782, 2010.
DOI : 10.3324/haematol.2009.015917

R. Niesvizky, P. Richardson, S. Rajkumar, M. Coleman, L. Rosiñol et al., The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma, British Journal of Haematology, vol.108, issue.1, pp.46-53, 2008.
DOI : 10.1111/j.1365-2141.2008.07303.x

B. Mohty, J. El-cheikh, I. Yakoub-agha, H. Avet-loiseau, P. Moreau et al., Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and « retreatment » approaches in the era of novel agents. Leukemia. 2012 janv, pp.73-85

A. Palumbo, T. Facon, P. Sonneveld, J. Bladè, M. Offidani et al., Thalidomide for treatment of multiple myeloma: 10 years later, Blood, vol.111, issue.8, pp.3968-77, 2008.
DOI : 10.1182/blood-2007-10-117457

M. Dimopoulos, A. Anagnostopoulos, and D. Weber, Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives, Journal of Clinical Oncology, vol.21, issue.23, pp.4444-54, 2003.
DOI : 10.1200/JCO.2003.07.200

D. Weber, C. Chen, R. Niesvizky, M. Wang, A. Belch et al., Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America, New England Journal of Medicine, vol.357, issue.21, pp.2133-2175, 2007.
DOI : 10.1056/NEJMoa070596

M. Dimopoulos, C. Chen, A. Spencer, R. Niesvizky, M. Attal et al., Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma, Leukemia, vol.23, issue.11, pp.2147-52, 2009.
DOI : 10.1056/NEJMoa0801479

P. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath et al., A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma, New England Journal of Medicine, vol.348, issue.26, pp.2609-2626, 2003.
DOI : 10.1056/NEJMoa030288

S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin et al., A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma, British Journal of Haematology, vol.16, issue.2, pp.165-72, 2004.
DOI : 10.1111/j.1365-2141.2004.05188.x

R. Orlowski, A. Nagler, P. Sonneveld, J. Bladé, R. Hajek et al., Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression, Journal of Clinical Oncology, vol.25, issue.25
DOI : 10.1200/JCO.2006.10.5460

S. Kumar, J. Lee, J. Lahuerta, G. Morgan, P. Richardson et al., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study, Leukemia, vol.16, issue.1, pp.149-57, 2012.
DOI : 10.1182/blood-2006-08-040410

M. Streetly, K. Gyertson, Y. Daniel, J. Zeldis, M. Kazmi et al., Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation, British Journal of Haematology, vol.24, issue.18, pp.41-51, 2008.
DOI : 10.1097/00001721-200204000-00003

S. Schey, P. Fields, J. Bartlett, I. Clarke, G. Ashan et al., Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma, Journal of Clinical Oncology, vol.22, issue.16
DOI : 10.1200/JCO.2004.10.052

M. Lacy, S. Hayman, M. Gertz, A. Dispenzieri, F. Buadi et al., Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma, Journal of Clinical Oncology, vol.27, issue.30, pp.5008-5022, 2009.
DOI : 10.1200/JCO.2009.23.6802

M. Khan and A. Stewart, Carfilzomib: a novel second-generation proteasome inhibitor, Future Oncology, vol.27, issue.5, pp.607-619, 2011.
DOI : 10.1158/1078-0432.CCR-09-0822

S. Lonial, R. Vij, J. Harousseau, T. Facon, P. Moreau et al., Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma, Journal of Clinical Oncology, vol.30, issue.16
DOI : 10.1200/JCO.2011.37.2649

W. Pönisch, M. Rozanski, H. Goldschmidt, F. Hoffmann, T. Boldt et al., Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial, British Journal of Haematology, vol.15, issue.Suppl.
DOI : 10.1111/j.1365-2141.2008.07076.x

R. Fenk, M. Michael, F. Zohren, T. Graef, A. Czibere et al., Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma, Leukemia & Lymphoma, vol.90, issue.12, pp.2345-51, 2007.
DOI : 10.1046/j.1365-2141.1998.00930.x

G. Gahrton, H. Svensson, M. Cavo, J. Apperly, A. Bacigalupo et al., Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres, British Journal of Haematology, vol.36, issue.1, pp.209-225, 2001.
DOI : 10.1038/sj.bmt.1701546

C. Crawley, S. Iacobelli, B. Björkstrand, J. Apperley, D. Niederwieser et al., Reducedintensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood, avr, vol.15109, issue.8, pp.3588-94, 2007.

F. Garban, M. Attal, M. Michallet, C. Hulin, J. Bourhis et al., Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma, Blood, vol.107, issue.9, pp.3474-80, 2006.
DOI : 10.1182/blood-2005-09-3869

B. Björkstrand, S. Iacobelli, U. Hegenbart, A. Gruber, H. Greinix et al., Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up, Journal of Clinical Oncology, vol.29, issue.22, pp.3016-3038, 2011.
DOI : 10.1200/JCO.2010.32.7312

A. Krishnan, M. Pasquini, B. Logan, E. Stadtmauer, and D. Vesole, Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial, The Lancet Oncology, vol.12, issue.13, pp.1195-203, 2011.
DOI : 10.1016/S1470-2045(11)70243-1

C. Crawley, M. Lalancette, R. Szydlo, M. Gilleece, K. Peggs et al., Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT, Blood, vol.105, issue.11, pp.4532-4541, 2005.
DOI : 10.1182/blood-2004-06-2387

B. Durie, J. Harousseau, J. Miguel, J. Bladé, B. Barlogie et al., International uniform response criteria for multiple myeloma, Leukemia, vol.27, issue.9, pp.1467-73, 2006.
DOI : 10.1038/sj.bmt.1703035

V. Jimenez-zepeda, J. Mikhael, A. Winter, N. Franke, E. Masih-khan et al., Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival, Biology of Blood and Marrow Transplantation, vol.18, issue.5, pp.773-782, 2012.
DOI : 10.1016/j.bbmt.2011.10.044

N. Shah, F. Ahmed, Q. Bashir, S. Qureshi, Y. Dinh et al., Durable remission with salvage second autotransplants in patients with multiple myeloma, Cancer, vol.26, issue.14
DOI : 10.1200/JCO.2007.14.2372

C. Blimark, L. Veskovski, J. Westin, S. Rödjer, M. Brune et al., Melphalan 100???mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation, European Journal of Haematology, vol.16, issue.2, pp.117-139, 2011.
DOI : 10.1016/j.bbmt.2010.04.002

G. Cook, E. Liakopoulou, R. Pearce, J. Cavet, G. Morgan et al., Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of??Blood and Marrow Transplantation Registry, Biology of Blood and Marrow Transplantation, vol.17, issue.11, pp.1638-1683, 2011.
DOI : 10.1016/j.bbmt.2011.04.005

R. Fenk, V. Liese, F. Neubauer, I. Bruns, M. Kondakci et al., Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation, Leukemia & Lymphoma, vol.114, issue.1, pp.1455-62, 2011.
DOI : 10.1038/bmt.2008.343

R. Olin, D. Vogl, D. Porter, S. Luger, S. Schuster et al., Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma, Bone Marrow Transplantation, vol.16, issue.5, pp.417-439, 2009.
DOI : 10.1182/blood-2007-07-101212

V. Jimenez-zepeda, J. Mikhael, A. Winter, N. Franke, E. Masih-khan et al., Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival, Biology of Blood and Marrow Transplantation, vol.18, issue.5, pp.773-782, 2012.
DOI : 10.1016/j.bbmt.2011.10.044

J. Burzynski, J. Toro, R. Patel, S. Lee, R. Greene et al., Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma, Leukemia & Lymphoma, vol.16, issue.9, pp.1442-1449, 2009.
DOI : 10.1038/sj.leu.2405062

S. Kumar, S. Mahmood, M. Lacy, A. Dispenzieri, S. Hayman et al., Impact of early relapse after auto-SCT for multiple myeloma, Bone Marrow Transplantation, vol.25, issue.6, pp.413-433, 2008.
DOI : 10.1056/NEJMoa032290

C. Lee, B. Barlogie, M. Zangari, A. Fassas, E. Anaissie et al., Transplantation as salvage therapy for high-risk patients with myeloma in relapse, Bone Marrow Transplantation, vol.19, issue.12, pp.873-881, 2002.
DOI : 10.1200/JCO.2001.19.16.3675

M. Wang, M. Dimopoulos, C. Chen, M. Cibeira, M. Attal et al., Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure, Blood, vol.112, issue.12, pp.4445-51, 2008.
DOI : 10.1182/blood-2008-02-141614

P. Sonneveld, R. Hajek, A. Nagler, A. Spencer, J. Bladé et al., Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy, Cancer, vol.100, issue.7, pp.1529-1566, 2008.
DOI : 10.1002/cncr.23326

J. San-miguel, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin et al., Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study, Leukemia, vol.16, issue.4, pp.842-851, 2008.
DOI : 10.1046/j.1365-2141.1998.00930.x

M. Dimopoulos, E. Kastritis, L. Rosinol, J. Bladé, and H. Ludwig, Pathogenesis and treatment of renal failure in multiple myeloma, Leukemia, vol.39, issue.8, pp.1485-93, 2008.
DOI : 10.1016/S0272-6386(12)81021-3

M. Attal, V. Lauwers-cances, G. Marit, D. Caillot, P. Moreau et al., Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.366, issue.19, pp.1782-91, 2012.
DOI : 10.1056/NEJMoa1114138

URL : https://hal.archives-ouvertes.fr/hal-00852275

M. Pineda-roman, M. Zangari, F. Rhee, . Van, E. Anaissie et al., VTD combination therapy with bortezomib|[ndash]|thalidomide|[ndash]|dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia, pp.1419-1446, 2008.

K. Andersen and . Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study, Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Post-Meetong Edition, 2009.